NCT06539962View on ClinicalTrials.gov

Interstitial Lung Disease is a Risk Factor for Cardiovascular Disease

CompletedOBSERVATIONAL
Enrollment

134

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2024

Study Completion Date

October 1, 2024

Conditions
Interstitial Lung DiseaseCardiovascular Morbidity
Interventions
DIAGNOSTIC_TEST

Krebs von den Lungen-6 (KL-6)

Krebs von den Lungen-6 (KL-6) will be evaluated for ability to predict cardiovascular comorbidities among IPF patients

Trial Locations (1)

711111

Faculty of Medicine, Assiut University, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT06539962 - Interstitial Lung Disease is a Risk Factor for Cardiovascular Disease | Biotech Hunter | Biotech Hunter